Journals / Turkish archives of pediatrics (Online) / 2021 / Cilt: 56 - Sayı: 1

Benign recurrent intrahepatic cholestasis type 2 in a child: A case report and novel mutation

Pages
72–74
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

This mutation (c.3083_3084delCAinsTG) in the ABCB11 gene is the first reported in a patient with benign recurrent intrahepatic cholestasis type 2.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Benign recurrent intrahepatic cholestasis is a rare disorder characterized by recurrent episodes of cholestatic jaundice without liver damage.
📊
Key Findings & Data:A mutation in the ABCB11 gene encoding bile salt export pump protein causes the disease.
💡
Conclusion & Impact:This mutation (c.3083_3084delCAinsTG) in the ABCB11 gene is the first reported in a patient with benign recurrent intrahepatic cholestasis type 2.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

Benign recurrent intrahepatic cholestasis is a rare disorder characterized by recurrent episodes of cholestatic jaundice without liver damage. A mutation in the ABCB11 gene encoding bile salt export pump protein causes the disease. A 16-year-old boy with severe jaundice is presented here. His laboratory tests were consistent with intrahepatic cholestasis despite having normal gamma-glutamyl transpeptidase levels. Acute and chronic liver diseases with viral, metabolic, and autoimmune etiology were excluded. Magnetic resonance imaging revealed normal intra- and extrahepatic bile ducts. A liver biopsy showed cholestasis in the centrilobular and intermediate zones and sinusoidal dilatation. Genetic testing revealed a homozygous c.3083_3084delCAinsTG (Ala1028Val) mutation in the ABCB11 gene. The patient was treated with ursodeoxycholic acid 20 mg/kg/day and cholestyramine 4 g twice daily, and total bilirubin decreased to normal ranges after two months of therapy. This mutation (c.3083_3084delCAinsTG) in the ABCB11 gene is the first reported in a patient with benign recurrent intrahepatic cholestasis type 2.

🔖

Cite This Article

AKBULUT, U. E., RANDA, N. C., IŞIK, İ. A., ATALAY, A. (2021). Benign recurrent intrahepatic cholestasis type 2 in a child: A case report and novel mutation. Turkish archives of pediatrics (Online), Cilt: 56 - Sayı: 1, 72–74. https://ajindex.com/articles/370009

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (1)

  1. Tai Y, Xie Y, Tang CW. Compound heterozygous mutations of ABCB11 responsible for benign recurrent intrahepatic cholestasis. J Dig Dis 2015; 16: 299-302. [Crossref] 2. van der Woerd WL, Houwen RH, van de Graaf SF. Current and future therapies for inherited cholestatic liver diseases. World J Gastroenterol 2017; 23: 763-75. [Crossref] 3. Sticova E, Jirsa M, Pawłowska J. New Insights in Genetic Cholestasis: From Molecular Mechanisms to Clinical Implications. Can J Gastroenterol Hepatol 2018: 2313675. [Crossref] 4. Luketic VA, Shiffman ML. Benign recurrent intrahepatic cholestasis. Clin Liver Dis 1999; 3: 509-28. [Crossref] 5. Dröge C, Bonus M, Baumann U, et al. Sequencing of FIC1, BSEP and MDR3 in a large cohort of patients with cholestasis revealed a high number of different genetic variants. J Hepatol 2017; 67: 1253-64. [Crossref] 6. Pan S, Li X, Jiang P, et al. Variations of ABCB4 and ABCB11 genes are associated with primary intrahepatic stones. Mol Med Rep 2015; 11: 434-46. [Crossref] 7. Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 2015; 17: 405-24. [Crossref] 8. Spiegel EL, Schubert W, Perrin E, Schiff L. Benign recurrent intrahepatic cholestasis with response to cholestyramine. Am J Med 1965; 39: 682-8. [Crossref] 9. Balsells F, Wyllie R, Steffen R, Kay M. Benign recurrent intrahepatic cholestasis: improvement of pruritus and shortening of the symptomatic phase with rifampin therapy: a case report. Clin Pediatr (Phila) 1997; 36: 483-5. [Crossref] 10. Gonzales E, Grosse B, Schuller B, et al. Targeted pharmacotherapy in progressive familial intrahepatic cholestasis type 2: evidence for improvement of cholestasis with 4-phenylbutyrate. Hepatology 2015; 62: 558-66. [Crossref]